Abre venous self-expanding stent found safe, effective in treating challenging deep venous lesions was approved by the FDA.
News | Venous Therapies
Medtronic Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obstruction

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic Abre venous self-expanding ...

Home October 26, 2020
Home
Patient case example of the FlowTriever thrombectomy device from Inari Medical Inc. in removing a pulmonary embolism and reporting blood flow and clot burden removed by the system. #TCT2020 #TCTconnect
News | Pulmonary Embolism
Acute Hemodynamic Improvement With Percutaneous Mechanical Thrombectomy in a Real-world Pulmonary Embolism Population

October 23, 2020 — Positive results were reported on the first 230 patients enrolled in its FLASH study, a real world ...

Home October 23, 2020
Home
Fractional Flow reserve (FFR) selection on the Abbott, St. Jude FFR system console. The TARGET FFR study at #TCT2020 #TCTconnect.
News | FFR Technologies
FFR-guided PCI Optimization Strategy May Lead to Improved Outcomes

October 23, 2020 – Results from the randomized controlled TARGET FFR trial show that while a physiology-guided ...

Home October 23, 2020
Home
An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone actually was not flow limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings. #TCT2020 #TCTconnect
News | FFR Technologies | Dave Fornell, Editor
FFR-CT Did Not Significantly Reduce Costs But Reduced Rates of Invasive Coronary Angiography

October 22, 2020 – In the FORECAST randomized clinical trial, the use of fractional flow reserve (FFR) derived from ...

Home October 22, 2020
Home
Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect
Feature | Stents | Dave Fornell, Editor
Durable Polymer Drug-Eluting Stents Perform Better Than Biodegradable Polymer DES

October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durable ...

Home October 22, 2020
Home
For patients undergoing percutaneous coronary intervention (PCI), treatment with the CeloNova Biosciences nanotechnology polymer-coated Cobra PzF stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy. #TCT #TCTconnect #TCT2020
News | Stents
Nano-Coated Coronary Stent and Shorter DAPT Did Not Meet Non-inferiority for Thrombotic Events

October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnology ...

Home October 22, 2020
Home
Videos | Hemodynamic Support Devices
VIDEO: Abiomed Highlights Trends and New Technology in Hemodynamic Support

Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the ...

Home October 20, 2020
Home
Videos | Coronavirus (COVID-19)
VIDEO: Use of Impella in COVID-19 Patients

Chuck Simonton, M.D., chief medical officer at Abiomed, explains when advanced hemodynamic support is required in COVID ...

Home October 20, 2020
Home
Videos | Cath Lab
VIDEO: Intravascular Lithotripsy to Treat Severely Calcified Coronary Artery Lesions

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

Home October 19, 2020
Home
Videos | Stents Drug Eluting
VIDEO: Results of the OPTIMIZE IDE Trial for the Svelte Drug Eluting Stent 

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

Home October 19, 2020
Home
Videos | Antiplatelet and Anticoagulation Therapies
VIDEO: Crushing Prasugrel Tablets Does Not Help STEMI Patients

The COMPARE CRUSH Trial looked at the effect of per-hospital crushed prasugrel tablets in patients with STEMI planned ...

Home October 19, 2020
Home
Videos | Heart Valve Technology
VIDEO: Results Mixed on Use of Cerebral Embolic Protection in TAVR From the STS/ACC TVT Registry

David Cohen, M.D., presents late-breaking data from the STS/ACC Transcatheter Valve Registry (TVT) showing the impact of ...

Home October 19, 2020
Home
Videos | Antiplatelet and Anticoagulation Therapies
VIDEO: Use of Shorten DAPT and the Xience Stent in High-bleeding Risk Patients

Roxana Mehran, M.D., and Marco Valgimiggle, M.D., present the results of the Xience 90/28 trials that evaluated the use ...

Home October 19, 2020
Home
Videos | Heart Valve Technology
VIDEO: General vs Local Anesthesia for TAVR Addressed in SOLVE-TAVI Trial

Doctor Hans-Josef Feistritzerm, Heart Center of Leipzig, Germany, presents data on the use of general vs. local ...

Home October 19, 2020
Home
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab
No Mortality Risk Associated With Paclitaxel-coated Devices Used to Treat Peripheral Artery Disease

October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit ...

Home October 18, 2020
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now